Insilico Medicine and Bora Pharmaceuticals announced a multi-target strategic alliance designed to connect Insilico's AI-native drug discovery platform with Bora's global drug development, manufacturing, and commercialization capabilities.

If fully implemented, the potential value of the proposed collaboration could exceed $2.5 billion, as the definitive agreements governing the alliance have yet to be finalized between the two parties.¹

What are the details of the alliance?

The partnership is expected to span two distinct dimensions. The first is drug discovery and development with Insilico's Pharma.AI platform, which covers target discovery, generative chemistry and molecule optimization, will be linked to Bora's formulation, chemistry, manufacturing and controls, regulatory development, scale-up, quality systems, supply chain, and commercial manufacturing expertise.¹ Together, the companies are aiming to build an end-to-end pathway from AI-generated molecule design through to patient-ready medicines.

The second dimension is organizational. Insilico expects to support Bora by strengthening AI capabilities across its global workforce, while also enhancing AI literacy across the organization.¹ The partnership is also expected to apply Insilico's AI tools to improve efficiency in manufacturing, supply chain, distribution, and corporate operations.¹ The decision now positions Bora as an AI-enabled pharmaceutical development and manufacturing company, instead of just a manufacturing partner.

Bobby Sheng, founder, chairman of Bora Group and CEO of Bora Pharmaceuticals, described the deal as a strategic evolution for the company. "This strategic alliance marks an important step in Bora's evolution from a leading pharmaceutical development and manufacturing partner into a broader drug innovation ecosystem," Sheng said. "AI is already transforming drug discovery, but its full potential will only be realized when that transformation extends across the entire development and manufacturing value chain. This is not simply about adding AI to existing processes; it is about reimagining how pharmaceutical products are developed, manufactured, and brought to patients."

What does each party bring?

Insilico holds a demonstrated track record of AI-accelerated preclinical development, and while traditional early-stage drug discovery typically takes between two and a half to four years, Insilico has consistently reached preclinical candidate nomination in an average of 12 to 18 months.¹

Insilico has also continued to be a player in the partnership and licensing space in the first half of 2026, as its deal with Bora marks the latest amongst a string of deals which include its $120 million drug discovery collaboration with Qilu Pharmaceuticals, a $2.75 billion research and licensing agreement with Eli Lilly, a collaboration with SK Biopharmaceuticals worth up to $2.5 billion, and most recently a $177 Million collaboration with CMS.

On the other hand, Bora contributes deep experience across the full development and manufacturing value chain, from formulation development through commercial-scale production and supply chain execution.

“Building on our collaborations with Takeda and SK Biopharmaceuticals in Asia-Pacific, this alliance with Bora further demonstrates Insilico's commitment to partnering with leading biopharmaceutical innovators across the region," said Alex Zhavoronkov, founder, co-CEO and chief business officer of Insilico Medicine. "Together with Bora, we aim to connect that discovery engine with the capabilities required to advance high-quality drug candidates through development, manufacturing, and potential commercialization."

What is Insilico's broader platform strategy?

Beyond drug discovery partnerships, Insilico is also developing Mmai Gym, a platform designed to serve as both a trainer and benchmark for scientific AI.² The tool enables organizations to train models for domain-specific reasoning and evaluate their performance on real-world pharmaceutical tasks, with Human Longevity and Liquid AI among its current partners.

The company describes the long-term ambition of the platform as advancing toward what it calls pharma superintelligence, or AI systems capable of end-to-end reasoning across the drug development process.²

Sources

1. Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development Insilico Medicine July 14, 2026 https://www.prnewswire.com/news-releases/insilico-medicine-and-bora-pharmaceuticals-announce-strategic-alliance-for-ai-driven-drug-discovery-and-development-302824911.html
2. Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines BioSpace January 22, 2026 https://www.biospace.com/press-releases/insilico-medicine-launches-science-mmai-gym-to-transform-frontier-llms-into-pharmaceutical-grade-scientific-engines